# Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma

> **NCT00091676** · PHASE3 · UNKNOWN · sponsor: **Biovest International** · enrollment: 629 (estimated)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **BIOLOGICAL:** FNHLId1
- **BIOLOGICAL:** KLH + GM-CSF

## Key facts

- **NCT ID:** NCT00091676
- **Lead sponsor:** Biovest International
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 629 (ESTIMATED)
- **Last updated:** 2012-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00091676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00091676, "Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00091676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*